RxDoctor Payments Data

Jennifer Ranson

Family · Saint Albans, WVNPI 1215284492

Payments from drug & device makers

$937in general payments, 2019–2025

Across 60 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$317
  • Astellas Pharma US Inc$158
  • GSK$102
  • Novo Nordisk$77
  • Lilly USA, LLC$49
  • Amgen$40
  • plus $194 from 8 others

What the payments were for

  • Food & beverage$937100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$937 in reported general payments places this provider in the 65th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$2,762
Medicare patients
72
Services billed
123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide120$139,894
JardianceEmpagliflozin96$87,396
EliquisApixaban71$74,970
JanuviaSitagliptin Phosphate60$54,516
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$30,361
LinzessLinaclotide20$26,520
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$26,130
TrulicityDulaglutide18$23,130
FarxigaDapagliflozin Propanediol14$21,732
EntrestoSacubitril/Valsartan12$21,252
JanumetSitagliptin Phos/Metformin Hcl17$19,571
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr30$16,149
SymbicortBudesonide/Formoterol Fumarate60$15,468
MounjaroTirzepatide12$11,467
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate54$9,812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$77$139,894120 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$102$53,79288 claims
AstraZenecaFarxiga, Symbicort$15$37,20074 claims
Lilly USA, LLCTrulicity, Mounjaro$49$34,59830 claims
AbbVieLinzess$317$26,52020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,507 family providers in West Virginia.

Other family in Saint Albans

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →